AQR Arbitrage’s Senti Biosciences Holdings SNTI Stock Holding History

AQR Arbitrage’s Portfolio SNTI Stock Details SNTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-21,751	Closed	-$2.15M	–	1518
2022 Q1	$2.15M	Hold	21,751	–	–	0.06%	348
2021 Q4	$2.15M	Hold	21,751	–	–	0.05%	375
2021 Q3	$2.16M	Hold	21,751	–	–	0.06%	262
2021 Q2	$2.16M	Buy	+21,751	New	+$2.17M	0.06%	241

Other funds holding SNTI

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CCM

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Intel Corp Santa Clara, California $470M AUM 21.74% 1-Year Est. Return

FMN

Financial Management Network Mission Viejo, California $653M AUM 17.76% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Kingfisher Capital Charlotte, North Carolina $437M AUM 41.72% 1-Year Est. Return

AQR Arbitrage's SNTI Position: Q2 2022 in Review

AQR Arbitrage sold out of Senti Biosciences Holdings (SNTI) in Q2 2022, closing a stake of 21,751 shares — an estimated $2.15M sold.

AQR Arbitrage first reported a position in SNTI in Q2 2021 and held it in 4 quarters. The position peaked at $2.16M in Q3 2021. 22 funds tracked by Wall St. Rank hold SNTI as of Q2 2022.

AQR Arbitrage reported no remaining Senti Biosciences Holdings position as of Q2 2022 after selling out during the quarter.
AQR Arbitrage sold 21,751 Senti Biosciences Holdings shares in Q2 2022, an estimated $2.15M.
AQR Arbitrage first reported a position in Senti Biosciences Holdings in Q2 2021 and held it in 4 quarters.
AQR Arbitrage's Senti Biosciences Holdings position peaked at $2.16M in Q3 2021.
22 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q2 2022.

Based on AQR Arbitrage's 13F filing for Q2 2022, filed 15 Aug 2022.